

# Validation Testing of Home Blood Pressure Monitoring Devices for the Upper Arm According to the ISO 81060-2:2018/ AMD 1:2020 Protocol

Saheb Singh<sup>1</sup>, Deepak Sinha<sup>2</sup>

<sup>1</sup>Project Manager, Mann Electronics India Pvt Ltd <sup>2</sup>Vice President, Mann Electronics India Pvt Ltd

### Abstract

The purpose of the study was to ascertain the accuracy of blood pressure monitors commonly available in the market and used in home care set-up. Six devices were chosen including one manufactured by Mann Electronics India Private Limited, Kota from the market. These devices did not have accessible validation testing results. The subjects for assessment were adults from the general population with varied age groups and sex. The objective was to establish whether the devices conform to the requirements of ISO 81060-2:2018/AMD1: 2020 protocol

### Introduction

The home care blood pressure monitors have become prevalent in today's fast moving society where time is at a premium and more often than not it is impractical to visit clinics for regular check-ups for optimum management of hypertension. This has led to proliferation of wide range of BP monitors in the market to guide diagnosis and treatment of hypertension. However, many of the BP Monitors available in the market are not validated and in the absence of systematic validation, the buyers may purchase a device which is inaccurate and therefore, the data is too risky to rely on for diagnosis and subsequent management of hypertension. The purpose of the study was to evaluate the accuracy of MANN BP Monitors and some other popular brands available in the market intended to be used in a home care set up to have an idea of their accuracy in providing BP readings.

### Methodology:

The devices chosen for the study are based on oscillometric principle. The medical devices other than MANN were purchased directly from medical stores and used for the study. All were having upper arm cuff. Medium and large cuff sizes were used to suit the different arm circumference of the subjects chosen for study. The ISO 81060-2:2018/AMD 1:2020 standard was followed for conducting the study.

### **Participants** / Population

The subjects for study chosen were from 19 to 67 years of age with medium and large cuff sizes and varying BMI. Some of the participants were blood pressure patients while others did not have a history of hypertension. The participants included a mix of male and female in the age group mentioned above.



All the participants were consulted and consented prior to including them in the study.

### Study team

The study was conducted by a panel of experienced qualified Doctors/ Technicians and project manager (study coordinator) who were all trained and certified in the basics of conducting validation studt of automatic BP devices.

Sl. No.	Name	Qualification	Hospital/Clinic/Organisation	Role
1.	Dr. Saket Goel	Cardiologist	Kota Heart Research Institute, Kota, Rajasthan, India	Team Leader, Validation Team
2.	Dr. Manoj Saluja	MD, Medicine	Govt. Medical College, Kota, Rajasthan, India	Member Validation team, Trainer and Observer
3.	Dr. G.D. Ramchandani	MD	G Ramchandani Clinic, Kota, Rajasthan, India	Member Validation Team, Trainer and Observer
4.	Ms. Taru Gulati	B. Com, MBA	MANN Electronics India Pvt. Ltd. Kota, Rajasthan, India	Project Manager and Study Coordinator

### **Devices Used for Study**

Device Name / Model no	Product Serial no
MANN	MEQ24003-0010
OMRON	202305001332V
AIcare	X522110700529
Meditek	MLPL 1729
Sanitas	656.33
Microlife	231705673

### **Blood pressure measurements**

The team comprising a panel of senior doctors as mentioned in the table above, reviewed and approved the study. The team was briefed on the methodology of taking observations so as to eliminate any bias in the observed readings. The participants' arms were measured as a reference to select an appropriate cuff size for BP measurements. Connected y-tube standard mercury sphygmomanometer duly calibrated was used for study. A dual head teaching stethoscope was used by the two observers to record simultaneous reference readings. The participants were rested for 5 minutes before baseline BP readings were taken with the reference BP Monitor. It was ensured that the observers were blinded to each other's recordings to eliminate any chance of bias while noting the observations. After recording the readings, they were



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

handed over to the Study Coordinator who evaluated whether the readings were within 4mmHg. Those readings which differed by more than 4 mm Hg were discarded in accordance with the standard requirement (Ref. ISO 81060-2:2018/AMD 1:2020). The test device was also used to obtain an initial reading. After both baseline readings were recorded, four reference mercury sphygmomanometer measurements were taken alternately with three test device measurements with 60 second rests observed between readings. Additional readings were taken to replace the excluded readings in order to complete three valid sets of reference, test device, reference BP comparisons. Readings were excluded for prespecified observer differences, blood pressure reading variation, participant body movement, talking or when one or both observers were unable to hear a reading. The subject was excluded if readings were repeated for a third time and the two observer's measurements were not within 4 mmHg. Furthermore, subjects with BP variability in reference BP measurements >12/8mm Hg between any two of the four reference BP measurements were excluded with the option to include from these subjects in the analysis two (instead of the three) consecutive valid pairs of reference measurements that fulfil the requirement provided this applied to no more than 10% of subjects.

#### The final study cohorts

In accordance with the requirements of ISO 81060-2:2018/AMD 1:2020, the objective was to include the participants with an adequate distribution of systolic and diastolic blood pressure, arm circumference and sex ratio to have a fair judgement of the validity of the outcome. Some additional ten participants were identified with the eligible measurements for replacement, in case some of the participants did not meet the study criteria. In any case, the number was restricted to eighty five.

#### Statistical analysis

As a first step the mean of the reference readings by the observers and the device readings were ascertained. Then, the difference between the device and the observers' measurements were calculated. The assessed means and standard deviations of the absolute values of the differences between the SBP and DBP measurements of the devices under test and the reference standard were calculated and compared with Criterion 1 of the ISO 81060-2:2018/AMD 1:2020 standard, viz., whether or not the means were  $\leq$ 5.0mm Hg and the standard deviation was  $\leq$ 8.0mm Hg. The Bland-Altman plots of the differences in SBP and DBP determinations by blood pressure (means of test device and observer measurements) and arm circumference values. We calculated the standard deviations of the differences of the averaged paired determinations of the device under test and the reference measurement for each subject and compared these to Criterion 2 of the ISO 81060-2:2018/AMD 1:2020 standard.

#### Results

The details of the participants screened, eligible participants, number removed and number included in the analysis are presented in Table 1. The process ensured that the group identified for study (85 participants) meets the requirement of ISO 81060-2: 2018/AMD 1: 2020 standard for systolic, diastolic blood pressure, sex and arm circumference for each of the devices. The participant characteristics of the group for all the devices are presented in Table 2. Details of the participant group for all the devices are presented in Table 2. Bland- Altman scatter plots of the differences between the



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

devices under test and the observer measurements for SBP and DBP against their average value are mentioned in Figs 1 to 6.

<b>S.</b>	Participant details			Observ	vations		
No		MANN	OMRON	Alcare	Meditek	Sanitas	Microlife
1	No. screened	85	85	85	85	85	85
2	No. excluded	0	0	0	0	0	0
3	Arrhythmia	0	0	0	0	0	0
4	Poor quality sounds	0	0	0	0	0	0
5	Difference in any two reference	0	0	0	0	0	0
	SBP by more than 12mm Hg or						
	DBP by more than 8mm Hg						
6	Inter-observer difference	0	0	0	0	0	0
	exceeding standard						
7	Persistent movement during	0	0	0	0	0	0
	measurement						
8	Arm circumference outside of	0	0	0	0	0	0
	range						
9	Pregnant	0	0	0	0	0	0
10	Other (participant body	0	0	0	0	0	0
	movement, talking, BP						
	Variation, Upper arm						
	Circumference <17 cm or >43						
	cm, etc)						
11	Total removed through blinded	0	0	0	0	0	0
	backwards selection						
12	Total included in analytic	85	85	85	85	85	85
	cohort						

 Table 1: Participant screening and elimination details

S.	Participant	MANN	OMRON	Alcare	Meditek	Sanitas	Microlife
No	characteristics						
	and reference						
	blood pressure						
	distribution						
1	Male (N): Female	51: 34	51: 34	51: 34	51: 34	51: 34	51: 34
	(N)						
2	Age years Range	19:67	19:67	19:67	19:67	19:67	19:67
	(Low: High)						
3	Mean (SD)	10.95/6.13	10.52/5.36	10.52/6.09	10.62/5.95	10.33/5.98	10.70/6.24
4	Arm Circumference	Small-41	Small-41	Small-41	Small-41	Small-41	Small-41
	(cm) Range (Low:	Nos	Nos	Nos	Nos	Nos	Nos



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

	Iliah	Madine					
	High	Medium-					
		19 Nos					
		Large-25					
		Nos					
5	SBP (mmHg)	95: 182	95:182	98:179	96:180	98:178	98:181
	Overall Range						
	(Low: High)						
6	≥160 (N: %)	2:0.78	2:0.78	2:0.78	2:0.78	2:0.78	2:0.78
7	≥140	2:0.78	2:0.78	2:0.78	2:0.78	2:0.78	2:0.78
8	≤100	1:0.4	1:0.4	1:0.4	1:0.4	1:0.4	1:0.4
9	DBP (mmHg)	60:110	60:109	63:108	60:109	60:110	63:110
	Overall Range						
	(Low: High)						
10	≥ 100 (N: %)	1:0.4	2:0.78	1:0.4	1:0.4	1:0.4	1:0.4
11	$\geq 85$	16:6.3	12:4.7	13:5.0	11:4.3	16:6.3	6:2.4
12	$\leq 60$	1:0.4	0:0	1:0.4	1:0.4	0:0	1:0.4

Table 2: Participant characteristics and reference blood pressure distribution

### **Bland-Altman Plots for BP Monitors under Test**



**Fig. 1 Bland-Altman Plots for MANN :** Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com



**Fig.2: Bland-Altman Plots for OMRON:** Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



Fig. 3: Bland-Altman Plots for AICare: Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com



Fig 4: Bland-Altman Plots for Meditek: Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



Fig 5: Bland-Altman Plots for Sanitas: Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



**Fig 6: Bland-Altman Plots for Microlife:** Bland–Altman Plots of the differences between the Mann measurements and observer measurements for (a) systolic blood pressure (SBP) and (b) diastolic blood pressure (DBP)



#### Strengths and limitations

Strengths of this study include the testing of multiple commercial home BP monitors under similar rigorous conditions and achieving the required distribution of subjects by arm size, blood pressure and sex. Limitations are that the study population was limited to a general adult population, and the generalization of these findings to other populations (e.g., pregnant women, children) is unknown. Additionally, while we

followed the recommendations for which data points to include or exclude from an expert consultant who trained the study team, we removed and repeated reference measurements with discrepant observer readings but did not remove and repeat the preceding test device measurement when the repeated reference measurement met the criteria for observer agreement.

While we believe that this choice is consistent with the ISO 81060-2:2018 + A1:2020 protocol, we acknowledge that this interpretation differs from the one described by other.

#### Summary

The importance of homecare BP monitoring is becoming increasingly important and is being recognized for hypertension diagnosis and management. However, many devices marketed for home use do not have published validation information available for testing them using an international standard. Under this circumstance, the accuracy of the available BP Monitor for home care is difficult to ascertain whereby a buyer might end up with un-calibrated device. This may lead to improper diagnosis and treatment of hypertension.

What this study adds is that the devices under test –MANN, Omron, Alcare, Meditek, Sanitas & Microlife are accurate enough for home use in a general adult population as they meet the applied ISO standard for home use.

#### **Data Availability**

Final study data is available by written request to the investigators.

#### Funding

This work was funded by Mann Electronics India Pvt Ltd. And they are solely responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation and approval of the manuscript; and decision to submit the manuscript for publication.

All analyses were conducted by Mann Electronics India Pvt Ltd employees. Employees of Mann Electronics India Pvt Ltd. participated and provided input into study meetings and reviewed the manuscript.

#### **Competing Interests**

The investigators reported receiving grant funding from Mann electronics India Pvt. Limited. The authors have no other disclosures to report.





E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

Annexure I
Participant Profile for Validation Study

ST				Cu	Reading (mmHg/SBP/DBP/PR per min)					
N 0.	Participan ts	M/ F	Ag e	ff Siz e	Mann	Omron	AIcare	Meditek	Sanitas	Microlife
1	Participant 1	F	40	26	108/76- 101	110/78-98	109/76- 103	110/78- 97	109/79- 98	106/79- 99
2	Participant 2	М	60	27	121/83- 63	119/80-62	120/81- 63	122/83- 60	118/79- 59	119/82- 62
3	Participant 3	М	42	29	110/81- 81	109/83-80	112/81- 80	110/82- 80	108/79- 82	109/80- 81
4	Participant 4	F	26	28	115/87- 106	118/85- 103	117/88- 105	115/87- 105	115/85- 106	114/84- 105
5	Participant 5	F	31	30	119/80- 79	121/82-80	118/79- 79	120/79- 82	119/81- 80	120/82- 79
6	Participant 6	F	32	19	114/65- 87	117/68-85	115/63- 86	113/64- 85	114/65- 86	116/63- 88
7	Participant 7	F	22	18	107/69- 82	109/71-80	105/67- 81	106/70- 80	108/70- 81	107/69- 82
8	Participant 8	F	22	20	97/62-69	95/60-70	98/63-68	96/60-70	98/60-68	98/60-70
9	Participant 9	F	24	21	116/84- 79	118/82-80	115/80- 80	117/83- 82	116/83- 78	114/83- 78
10	Participant 10	F	23	21	124/88- 79	122/86-82	125/87- 80	123/85- 70	126/88- 79	123/87- 78
11	Participant 11	F	24	21	121/83- 63	119/80-62	120/81- 63	122/83- 60	118/79- 59	119/82- 62
12	Participant 12	F	24	20	108/76- 101	110/81-98	114/76- 103	119/78- 97	120/79- 98	126/79- 99
13	Participant 13	F	32	20	121/83- 63	119/80-62	120/81- 63	122/83- 60	118/79- 59	119/82- 62
14	Participant 14	F	31	21	110/81- 81	109/83-80	112/81- 80	110/82- 80	108/79- 82	109/80- 81
15	Participant 15	F	31	22	115/87- 106	118/85- 103	117/88- 105	115/87- 105	115/85- 106	114/84- 105
16	Participant 16	М	45	34	180/110- 81	182/109- 82	179/108- 82	180/109- 81	178/110- 83	181/110- 82
17	Participant 17	М	47	34	169/99- 102	167/100- 101	170/98- 102	169/99- 100	168/99- 101	169//99- 102
18	Participant	Μ	40	33	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-



E-ISSN: 2582-2160 • Website: www.ijfmr.com

• Email: editor@ijfmr.com

	18				78		80	80	79	80
10	Participant	м	4.4	27	119/79-	121/82-	118/80-	120/79-	122/80-	119/79-
19	19	IVI	44	32	102	100	101	102	102	100
20	Participant	Б	21	21	115/87-	118/85-	117/88-	115/87-	115/85-	114/84-
20	20	Г	51	51	106	103	105	105	106	105
21	Participant	М	10	20	116/84-	110/02 00	115/80-	117/83-	116/83-	114/83-
21	21	IVI	19	20	79	110/02-00	80	82	78	78
22	Participant	м	45	21	128/78-	126/77 81	129/79-	129/81-	128/78-	129/79-
	22	111	43	21	78	120/77-01	80	80	79	80
22	Participant	м	67	24	130/86-	128/84 08	128/85-	125/84-	129/87-	128/84-
23	23	111	07	24	102	120/04-90	100	101	97	98
24	Participant	м	34	$\gamma\gamma$	128/78-	126/77 81	129/79-	129/81-	128/78-	129/79-
24	24	111	54		78	120/77-01	80	80	79	80
25	Participant	м	28	20	118/80-	121/82 80	119/79-	117/79-	118/81-	120/79-
23	25	101	20	29	82	121/02-00	81	80	81	80
26	Participant	F	30	25	129/81-	128/78 70	126/77-	129/79-	128/78-	129/79-
20	26	1	30	23	80	120/70-79	81	80	78	80
27	Participant	м	32	10	117/88-	115/87-	115/87-	118/85-	115/85-	114/84-
27	27	111	32	19	105	105	106	103	106	105
28	Participant	м	35	30	129/81-	128/78 70	129/79-	128/78-	126/77-	129/79-
20	28	101	55	30	80	120/70-79	80	78	81	80
29	Participant	м	30	31	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
2)	29	111	50	51	63	117/00/02	63	60	59	62
30	Participant	м	30	32	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
50	30	111	50	52	63	117/00-02	63	60	59	62
31	Participant	м	35	36	129/81-	128/78-79	126/77-	129/79-	128/78-	129/79-
51	31	111	55	50	80	120/10/17	81	80	78	80
32	Participant	м	38	37	129/81-	128/78-79	129/79-	128/78-	126/77-	129/79-
52	32	111	50	57	80	120/10/19	80	78	81	80
33	Participant	М	32	28	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
- 55	33	111	52	20	63	119/00/02	63	60	59	62
34	Participant	М	33	39	129/79-	129/81-80	126/77-	128/78-	129/79-	128/78-
51	34	111	55	37	80	129/01/00	81	79	80	78
35	Participant	м	33	39	129/79-	129/81-80	128/78-	129/79-	128/78-	126/77-
55	35	111	55	37	80	129/01/00	79	80	78	81
36	Participant	м	33	28	121/83-	119/80-67	120/81-	122/83-	118/79-	119/82-
50	36	111	55	20	63	119/00/02	63	60	59	62
37	Participant	М	33	318	118/80-	121/82-80	119/79-	117/79-	118/81-	120/79-
	37	111	55	210	82	121/02/00	81	80	81	80
38	Participant	м	32	22	129/81-	128/78-79	126/77-	129/79-	128/78-	129/79-
- 50	38	141	52		80	120,1017	81	80	78	80
39	Participant	F	25	21	119/79-	121/82-	118/80-	120/79-	122/80-	119/79-



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

• Email: editor@ijfmr.com

	39				102	100	101	102	102	100
40	Participant	Б	20	20	119/78-	120/70.09	126/79-	108/76-	110/81-	114/76-
40	40	Г	28	20	97	120/79-98	99	101	98	103
41	Participant	М	25	10	108/76-	110/01 00	114/76-	119/78-	120/79-	126/79-
41	41	IVI	33	19	101	110/81-98	103	97	98	99
40	Participant	Б	20	10	107/69-	100/71.90	105/67-	106/70-	108/70-	107/69-
42	42	Г	28	10	82	109//1-80	81	80	81	82
12	Participant	Б	20	26	121/83-	110/20 62	120/81-	122/83-	118/79-	119/82-
43	43	Г	50	20	63	119/00-02	63	60	59	62
11	Participant	м	25	25	128/78-	126/77 81	129/79-	129/81-	128/78-	129/79-
44	44	111	55	55	78	120/77-01	80	80	79	80
15	Participant	м	35	27	110/82-	108/70 82	109/80-	110/81-	109/83-	112/81-
43	45	101	55	21	80	100/79-02	81	81	80	80
16	Participant	м	32	31	115/87-	115/85-	114/84-	115/87-	118/85-	117/88-
-0	46	111	52	51	105	106	105	106	103	105
17	Participant	м	30	20	120/79-	110/81_80	120/82-	121/78-	118/80-	120/82-
+/	47	111	50	20	82	117/01-00	79	80	81	80
18	Participant	F	29	20	115/87-	115/85-	114/84-	113/85-	116/88-	115/86-
40	48	1	2)	20	105	106	105	102	104	104
10	Participant	F	38	18	119/79-	121/82-	118/80-	120/79-	122/80-	119/79-
<del>ر ب</del>	49	I	50	10	102	100	101	102	102	100
50	Participant	М	35	19	120/79-	122/80-	119/79-	119/79-	121/82-	118/80-
50	50	111	55	17	102	102	100	102	100	101
51	Participant	F	32	21	108/76-	110/81-98	114/76-	119/78-	120/79-	126/79-
51	51	1	52	21	101	110/01/20	103	97	98	99
52	Participant	F	30	21	118/80-	121/82-80	119/79-	117/79-	118/81-	120/79-
52	52	1	50	21	82	121/02/00	81	80	81	80
53	Participant	F	31	22	129/81-	128/78-79	126/77-	129/79-	128/78-	129/79-
- 55	53	1	51		80	120/10/19	81	80	78	80
54	Participant	F	39	27	120/79-	119/81-80	120/82-	119/80-	121/82-	118/79-
51	54	•	57	27	82	119/01/00	79	79	80	79
55	Participant	F	45	31	115/87-	115/85-	114/84-	115/87-	118/85-	117/88-
	55	-	10	51	105	106	105	106	103	105
56	Participant	М	34	30	122/83-	118/79-59	119/82-	121/83-	119/80-	120/81-
50	56		51	50	60	110/19 59	62	63	62	63
57	Participant	М	28	22	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
	57				63	119/00/02	63	60	59	62
58	Participant	М	28	21	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-
Ľ	58	-'*			78	120,77 01	80	80	79	80
59	Participant	М	27	22	119/79-	121/82-	118/80-	120/79-	122/80-	119/79-
	59	111			102	100	101	102	102	100
60	Participant	Μ	29	21	120/79-	122/80-	119/79-	119/79-	121/82-	118/80-



E-ISSN: 2582-2160 • Website: www.ijfmr.com

• Email: editor@ijfmr.com

	60				102	102	100	102	100	101
<i>c</i> 1	Participant	м	25	20	121/83-	110/00 62	120/81-	122/83-	118/79-	119/82-
01	61	IVI	55	20	63	119/80-02	63	60	59	62
62	Participant	Б	32	19	110/81-	100/83 80	112/81-	110/82-	108/79-	109/80-
02	62	Г	52	10	81	109/03-00	80	80	82	81
63	Participant	м	32	10	115/87-	118/85-	117/88-	115/87-	115/85-	114/84-
03	63	IVI	52	19	106	103	105	105	106	105
64	Participant	м	30	10	122/83-	118/70-50	119/82-	121/83-	119/80-	120/81-
04	64	101	50	17	60	110/79-39	62	63	62	63
65	Participant	м	28	18	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
05	65	101	20	10	63	117/00-02	63	60	59	62
66	Participant	м	35	41	128/85-	125/84-	129/87-	128/84-	130/86-	128/84-
00	66	171	55	11	100	101	97	98	102	98
67	Participant	М	35	21	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-
07	67	171	55	21	78	120/77 01	80	80	79	80
68	Participant	М	35	22	108/76-	110/81-98	114/76-	119/78-	120/79-	126/79-
00	68	171	55		101	110/01/20	103	97	98	99
69	Participant	М	29	22	115/87-	118/85-	117/88-	115/87-	115/85-	114/84-
07	69	171	2)		106	103	105	105	106	105
70	Participant	М	25	19	119/80-	121/82-80	118/79-	120/79-	119/81-	120/82-
70	70	171	23	17	79	121/02 00	79	82	80	79
71	Participant	М	26	21	114/65-	117/68-85	115/63-	113/64-	114/65-	116/63-
, <u>1</u>	71	171	20	21	87	117/00/05	86	85	86	88
72	Participant	F	35	29	130/86-	128/84-98	128/85-	125/84-	129/87-	128/84-
12	72	1	55	27	102	120/01/20	100	101	97	98
73	Participant	М	38	28	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-
15	73	171	50	20	78	120,77 01	80	80	79	80
74	Participant	М	38	20	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
<i>,</i> .	74	171	50	20	63	119/00/02	63	60	59	62
75	Participant	М	35	38	120/79-	122/80-	119/79-	119/79-	121/82-	118/80-
10	75		55	20	102	102	100	102	100	101
76	Participant	М	42	36	129/87-	128/84-98	130/86-	128/84-	128/85-	125/84-
	76			00	97	120/01/20	102	98	100	101
77	Participant	М	38	41	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-
	77		50		78	120,77 01	80	80	79	80
78	Participant	М	35	40	118/80-	121/82-80	119/79-	117/79-	118/81-	120/79-
	78				82	121/02 00	81	80	81	80
79	Participant	М	28	19	121/83-	119/80-62	120/81-	122/83-	118/79-	119/82-
. ,	79				63		63	60	59	62
80	Participant	F	32	37	128/78-	126/77-81	129/79-	129/81-	128/78-	129/79-
	80	-	52	57	78	1_0, , , 01	80	80	79	80
81	Participant	F	33	35	119/79-	121/82-	118/80-	120/79-	122/80-	119/79-



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

• Email: editor@ijfmr.com

	81				102	100	101	102	102	100
02	Participant	Б	24	31	120/79-	122/80-	119/79-	119/79-	121/82-	118/80-
02	82	Г	54		102	102	100	102	100	101
02	Participant	Б	42	18	108/76-	110/81-98	114/76-	119/78-	120/79-	126/79-
05	83	Г	42		101		103	97	98	99
01	Participant	Б	20	27	118/80-	101/00 00	119/79-	117/79-	118/81-	120/79-
04	84	Г	28	27	82	121/82-80	81	80	81	80
05	Participant	Б	20	26	129/81-	100/70 70	126/77-	129/79-	128/78-	129/79-
03	85	Г	32	20	80	120/78-79	81	80	78	80

\* For privacy reasons the Name of participants kept confidential

### Abbreviations

S No	Abbreviation	Full form
1	ISO	International Organisation for Standardisation
2	AMD	Amendment
3	SD	standard. Mean
4	SBP	Systolic blood pressure
5	DBP	Diastolic blood pressure
6	CVS	Cardiovascular disease
7	pp	Pulse pressure
8	MAP	Mean arterial pressure
9	mmHg	Millimetres in mercury
10	AHA	American Heart Association

### References

- Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2018;71:1269-1324. Erratum in: Hypertension. 2018; 71:e136-e139. Erratum: Hypertension 2018;71:e13-e115.
- 2. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–57.
- 3. Siu AL, U S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:778–86.
- 4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
- 5. Ulusoy Ş, Özkan G, Arıcı M, Derici Ü, Akpolat T, Şengül Ş, et al. Which out-of-office measurement technique should be used for diagnosing hypertension in prehypertensives? J Hum Hypertens. 2020;34:586–92.



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

- 6. Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: asystematic review. J Hypertension. 2017;35:421–41.
- 7. Jung M-H, Kim G-H, Kim J-H, Moon K-W, Yoo K-D, Rho T-H, et al. Reliability of home blood pressure monitoring: in the context of validation and accuracy. Blood Press Monit. 2015;20:215–20.
- ANSI/AAMI/ISO 81060-2:2019 Non-invasive sphygmomanometers—Part 2: Clinical investigation of intermittent automated measurement type. 2018. https:// www.iso.org/standard/73339.html. Accessed 20 July 2022.
- 9. ISO 81060-2:2018/AMD 1:2020 Non-invasive sphygmomanometers—Part 2: Clinical investigation of intermittent automated measurement type—Amendment International Organization for Standardization. 2020. https://www.iso.org/standard/75432.html. Accessed 20 July 2022.
- 10. Picone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. Validation Status of Blood Pressure Measuring Devices Sold Globally. JAMA. 2022;327:680–1.
- 11. Picone DS, Deshpande RA, Schultz MG, Fonseca R, Campbell NRC, Delles C, et al. Nonvalidated Home Blood Pressure Devices Dominate the Online Marketplace in Australia: Major Implications for Cardiovascular Risk Management. Hypertension. 2020;75:1593–9.
- 12. Akpolat T, Dilek M, Aydogdu T, Adibelli Z, Erdem DG, Erdem E. Home sphygmomanometers: validation versus accuracy. Blood Press Monit. 2009;14:26–31.
- 13. Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FR, et al. Accuracy of bloodpressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. Br J Gen Pr. 2020;70:e548–e554.
- 14. Picone DS, Padwal R, Campbell NRC, Boutouyrie P, Brady TM, Olsen MH, et al. How to check whether a blood pressure monitor has been properly validated for accuracy. J Clin Hypertens. 2020;22:2167–74.